3. Survival analysis of nine DEGs that significantly associated with prognosis of TNBC patients in TNBC, HER2+, and ER+ patients .
| Gene Name | Ensembl Gene ID | TNBC | HER2+ | ER+ | |||||||||||
| HR | L95 | U95 | Padj1 | HR | L95 | U95 | Padj1 | HR | L95 | U95 | Padj1 | ||||
| DEGs: differentially expressed genes; HR: hazard ratio; L95: lower 95% confidence interval; U95: upper 95% confidence interval; 1Cox regression adjusted for age and AJCC pathologic tumor stage; *Hormone-related gene. | |||||||||||||||
| FSIP1 | ENSG00000150667 | 4.61 | 1.52 | 13.99 | 6.92E-03 | 1.26 | 0.43 | 3.65 | 6.76E-01 | 0.38 | 0.16 | 0.89 | 2.58E-02 | ||
| ADCY5* | ENSG00000173175 | 0.22 | 0.07 | 0.67 | 7.53E-03 | 1.23 | 0.41 | 3.69 | 7.10E-01 | 0.75 | 0.34 | 1.62 | 4.60E-01 | ||
| FSD1 | ENSG00000105255 | 0.20 | 0.06 | 0.66 | 8.11E-03 | 0.49 | 0.16 | 1.52 | 2.19E-01 | 1.29 | 0.59 | 2.81 | 5.16E-01 | ||
| HMSD | ENSG00000221887 | 0.24 | 0.08 | 0.73 | 1.13E-02 | 0.18 | 0.02 | 1.44 | 1.07E-01 | 0.72 | 0.32 | 1.61 | 4.17E-01 | ||
| CMTM5 | ENSG00000166091 | 0.28 | 0.09 | 0.81 | 1.94E-02 | 1.03 | 0.34 | 3.06 | 9.64E-01 | 0.38 | 0.16 | 0.91 | 3.03E-02 | ||
| AFF3 | ENSG00000144218 | 0.29 | 0.10 | 0.86 | 2.63E-02 | 0.87 | 0.30 | 2.54 | 8.01E-01 | 0.90 | 0.43 | 1.88 | 7.71E-01 | ||
| CYP2A7* | ENSG00000198077 | 2.99 | 1.09 | 8.21 | 3.36E-02 | 0.75 | 0.25 | 2.23 | 6.00E-01 | 0.70 | 0.31 | 1.56 | 3.79E-01 | ||
| ATP1A2* | ENSG00000018625 | 2.86 | 1.01 | 8.05 | 4.73E-02 | 1.34 | 0.44 | 4.03 | 6.08E-01 | 0.56 | 0.25 | 1.24 | 1.55E-01 | ||
| C11orf86 | ENSG00000173237 | 0.34 | 0.12 | 0.99 | 4.98E-02 | 1.06 | 0.35 | 3.24 | 9.15E-01 | 1.20 | 0.55 | 2.62 | 6.51E-01 | ||